Isella, V

The Scales for Outcomes in Parkinson’s disease-Cognition (SCOPA-Cog) has been shown to be a clinimetrically rigorous and valid instrument for a disease-oriented neuropsychological assessment of Parkinson’s disease (PD) patients. In the present study we evaluated the psychometric properties of the Italian version of the SCOPA-Cog in 121 PD patients. The scale explores memory, attention, and […]

Hattori, T., Yuasa, T., Aoki, S., Sato, R., Sawaura, H., Mori, T., Mizusawa, H.

Background and Purpose: Previous neuropathologic studies in chronic hydrocephalus have suggested the presence of white matter damage, presumably from mechanical pressure due to ventricular enlargement and metabolic derangement. This study aimed to investigate the diffusional properties of the CST in patients with iNPH by using DTI and to determine whether this method could be used […]

Freund, Hans-Joachim, Kuhn, Jens, Lenartz, Doris, Mai, Jürgen K., Schnell, Thomas, Klosterkoetter, Joachim, Sturm, Volker

Background: Dementia represents one of the most challenging health problems. Despite intense research, available therapies have thus far only achieved modest results. Deep brain stimulation (DBS) is an effective treatment option for some movement disorders and is under study for psychiatric applications. Recently, diencephalic DBS revealed selective effects on memory functions, another facet of subcortical […]

Emre, Murat, Poewe, Werner, De Deyn, Peter Paul, Barone, Paolo, Kulisevsky, Jaime, Pourcher, Emmanuelle, van Laar, Teus, Storch, Alexander, Micheli, Federico, Burn, David, Durif, Frank, Pahwa, Rajesh, Callegari, Francesca, Tenenbaum, Nadia, Strohmaier, Christine

Objective: This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.; Methods: This was a 76-week, prospective, open-label, randomized study in patients aged 50 to 85 years. Primary outcomes included incidence of, and discontinuation due to, predefined […]

Caslake, Robert, Summers, Fiona, McConachie, Douglas, Ferris, Catriona, Gordon, Joanna, Harris, Clare, Caie, Linda, Counsell, Carl

Background: Cognitive decline is common in Parkinson’s disease (PD) but may not be adequately identified by the mini-mental state examination (MMSE), which is better suited to Alzheimer’s disease. The mini-mental Parkinson (MMP) examination is a cognitive screening tool designed in French specifically for PD. We aimed to establish the validity and reliability of the English […]

Arnaldi, Dario, Campus, Claudio, Ferrara, Michela, Famà, Francesco, Picco, Agnese, De Carli, Fabrizio, Accardo, Jennifer, Brugnolo, Andrea, Sambuceti, Gianmario, Morbelli, Silvia, Nobili, Flavio

Subtle cognitive impairment can be detected in early Parkinson’s disease (PD). In a consecutive series of de novo, drug-naive PD patients, we applied stepwise regression analysis to assess which clinical, neuropsychological, and functional neuroimaging (dopamine transporter [DAT] and perfusion single photon emission computed tomography [SPECT]) characteristics at baseline was predictive of cognitive decline during an […]

Aarsland, Dag, Ballard, Clive, Walker, Zuzana, Bostrom, Fredrik, Alves, Guido, Kossakowski, Katja, Leroi, Iracema, Pozo-Rodriguez, Francisco, Minthon, Lennart, Londos, Elisabet

Background: Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are common forms of dementia that substantially affect quality of life. Currently, the only treatment licensed for PDD is rivastigmine, and there are no licensed treatments for DLB. We aimed to test the safety and efficacy of the N-methyl D-aspartate (NMDA) receptor antagonist memantine […]